Search | Clinical Trials Finder

Conditions: Epilepsy
Interventions: E2007 (perampanel), Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 70 Years
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Little Rock, Arkansas • Tampa, Florida • Detroit, Michigan + 2 more

Conditions: Breast Cancer
Interventions: bevacizumab, capecitabine, cyclophosphamide, docetaxel, doxorubicin hydrochloride (Adriamycin), gemcitabine hydrochloride; Biological · Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 1,206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 432
States / cities: Little Rock, Arkansas • Castro Valley, California • Fremont, California + 287 more

Conditions: Pancreas Cancer
Interventions: GI-4000, Gemcitabine; Biological · Drug
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 18
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 14 more

Conditions: Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin, Basal Cell Cancer of the Skin, Breast Cancer
Interventions: Poly-ICLC; Drug
Lead sponsor: Nina Bhardwaj; Other
Eligibility: 14 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma
Interventions: Nivolumab, Ipilimumab + nivolumab, Pembrolizumab, Dabrafenib + trametinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Renal Cell Carcinoma
Interventions: Pembrolizumab, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 994 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 62
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 52 more

Conditions: Sleep Disturbance, Fatigue, Inflammatory Bowel Disease
Interventions: Behavioral Counseling, bupropion-SR; Behavioral · Drug
Lead sponsor: Eva Szigethy; Other
Eligibility: 15 Years to 30 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Persistent Atrial Fibrillation
Interventions: Catheter Ablation; Procedure
Lead sponsor: Stavros E Mountantonakis; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Manhasset, New York • New Hyde Park, New York • New York, New York

Conditions: Pain, Postoperative, Opioid Use
Interventions: Gabapentin, Placebos; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pancreas Cancer, Pancreas Adenocarcinoma
Interventions: Capecitabine; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV Infections
Interventions: Aluminum hydroxide, QS-21, rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1995
U.S. locations: 4
States / cities: St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 1 more

Conditions: Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
Interventions: aldesleukin, incomplete Freund's adjuvant, telomerase: 540-548 peptide vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Depressive Disorder, Major, Anhedonia
Interventions: Aticaprant, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 39
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more

Conditions: Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions: Valproic Acid Solution, Isotonic saline solution; Drug
Lead sponsor: Westat; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Osteosarcoma
Interventions: pre-surgical chemotherapy; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1987 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: COVID-19
Interventions: XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose); Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 54 Years
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 30
States / cities: Mobile, Alabama • Sacramento, California • Colorado Springs, Colorado + 26 more

Conditions: Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions: Laboratory Biomarker Analysis, Radiation Therapy, TLR4 Agonist GLA-SE; Other · Radiation · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Renal Cell Carcinoma, Kidney Cancer
Interventions: Durvalumab, Tremelimumab; Drug
Lead sponsor: Moshe Ornstein; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Cleveland, Ohio

Conditions: Multiple Myeloma
Interventions: MAGE-A3, MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY; Biological
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Unresectable or Metastatic Melanoma
Interventions: Ipilimumab, NY-ESO-1 Protein Vaccine, NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide, NY-ESO-1 OLP4 Vaccine with Poly-ICLC; Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: New York, New York • Pittsburgh, Pennsylvania • Charlottesville, Virginia

Conditions: Glioblastoma, Glioblastoma Multiforme
Interventions: MBM-02; Drug
Lead sponsor: Matrix Biomed, Inc.; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Neoplasms
Interventions: Abemaciclib, Standard Adjuvant ET, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 13
States / cities: Glendale, Arizona • Los Angeles, California • Hollywood, Florida + 7 more

Conditions: Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
Interventions: Soticlestat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 56 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 26
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 19 more

Search by objective public record fields.

E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer

Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease

ARIADNE Clinical Trial

A Prospective Randomized Double Blind Trial to Assess the Effect of a Single Preoperative Dose of Gabapentin on Postoperative Opioid Consumption in Patients Undergoing Rhinoplasty

CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.

Vaccine Therapy in Treating Patients With Metastatic Cancer

STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO)

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients

Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study

A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)

A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome